Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide
Clinical Trials in China / NCT06673121
Recruiting Observational

Respiratory Disease Cohort Studies of Chinese Medicine for Pulmonary Nodule

NCT06673121 · tracked via the Priya Life Science China tracker
Sponsor
Third Affiliated Hospital of Henan University of Traditional Chinese Medicine
Phase
Observational
Started
2024-01-03
Last updated
2024-11-04

Condition(s) studied

Pulmonary NoduleCohort StudyTraditional Chinese Medicine

Investigational drug(s) / intervention(s)

Traditional Chinese Medicine

Traditional Chinese Medicine: Received treatment with traditional Chinese medicine

Study summary

This study is a prospective multicenter cohort study that primarily evaluates the impact of traditional Chinese medicine treatment on pulmonary nodules

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: ① Patients with pulmonary nodules and recommended for follow-up by MDT; ② Voluntarily sign the informed consent form. Exclusion Criteria: ①Patients with metastatic pulmonary nodules; ②Patients with benign diseases such as pulmonary lymph nodes, hamartomas, sclerosing alveolar cell tumors, or nodules with obvious benign features such as calcification; ③Patients withserious heart, lung, liver and kidney diseases.

Primary outcome measure(s)

  • Pulmonary nodule growth — Low risk pulmonary nodules measure at month 12, 24,36,48 and60. Medium risk pulmonary nodules measure at month 6,12,18,24,30,36,42,48,54and 60. High risk pulmonary nodules measure at 3,6,9,12,15,18,21,24,27,30, 33,36,39,42,45,48,51,54,57 and 60.
    Enlargement of pulmonary nodules or appearance of new pulmonary nodules
  • Pulmonary nodule regression — Low risk pulmonary nodules measure at month 12, 24,36,48 and60. Medium risk pulmonary nodules measure at month 6,12,18,24,30,36,42,48,54and 60. High risk pulmonary nodules measure at 3,6,9,12,15,18,21,24,27,30, 33,36,39,42,45,48,51,54,57 and 60.
    Shrinkage or disappearance of pulmonary nodules

Trial sites (1)

FacilityCityRegionStatus
The Third Affiliated Hospital of Henan University of Traditional Chinese Medicine Zhengzhou Henan Recruiting

Other trials for the same condition

Remimazolam for Bronchoscopy in High-Risk Patients Recruiting
Risks and Benefits of Radiofrequency Ablation for Chronic Venous Insufficiency (CEAP C3-C6) in Patients Aged 80 and Over Recruiting
Video Double-Lumen Tube for Secondary Pulmonary Resection Starting soon
Natural Course and Therapeutic Effect of Recurrent Acute Pancreatitis Recruiting
Efficacy of Fuzheng Tongfu Jiedu Prescription for Treating Gastrointestinal Dysfunction Associated With Sepsis Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06673121 on ClinicalTrials.gov ↗ ← All trials in China